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vs. 42.3 6 35.3 pg/mL, P , 0.05) and monocyte chemoattractantDialysis solution containing hyaluronan: Effect on peritoneal
protein-1 MCP-1 (72.0 6 86.5 vs. 402.4 6 258.3 pg/mL, P ,permeability and inflammation in rats.
0.02), compared with rats treated with Dianeal alone. TheBackground. Hyaluronan (HA), a high molecular weight
thickness of the peritoneal interstitium showed a similar in-mucopolysaccharide found in interstitial tissues and fluid, is
crease in both groups, but mesenteric tissue from the HA grouplost from the peritoneal cavity during peritoneal dialysis. In
order to determine the role of HA in peritoneal function, contained more HA (48%, P , 0.01) than tissue from control
we investigated the effects of exogenous HA on peritoneal animals.
permeability, markers of intraperitoneal inflammation, and Conclusions. The addition of HA to peritoneal dialysis solu-
peritoneal morphology in rats exposed to peritoneal dialysis tion decreases protein permeability, increases ultrafiltration,
solution for four weeks. and decreases cytokine levels and the proportion of peritoneal
Methods. Wistar rats were infused intraperitoneally, twice neutrophils in dialysate from rats exposed to hypertonic dialysis
daily, with conventional, hypertonic dialysis solution (Dianeal solution. These results suggest that exogenous HA may help
3.86%; control) or Dianeal solution containing 10 mg/dL of to protect the peritoneal membrane during exposure to dialysis
high molecular weight HA. Peritoneal permeabilities and clear- solutions. These benefits, if sustained in the clinical setting, could
ances of solutes and protein were determined using a modified lead to improvements in the therapy of peritoneal dialysis.
peritoneal permeability test (peritoneal equilibration test) at
the beginning and the end of the treatment. Peritoneal volume
and ultrafiltration were determined using a macromolecular
In uremic patients treated with peritoneal dialysis, themarker and by gravimetric methods. Peritoneal inflammation
was determined by cell counts and differential and by the morphology and function of the peritoneal membrane
measurement of cytokine concentrations in the dialysate efflu- gradually deteriorate in a manner proportional to the du-
ent. Peritoneal thickness and HA content were determined in ration of dialysis [1, 2]. These changes are believed to beliver and mesentery biopsies taken at the end of the experiment.
due to the bioincompatibility of dialysis solutions or toResults. After four weeks of exposure to the dialysis solu-
tion, transperitoneal protein equilibration was significantly chronic inflammation induced by dialysis therapy [3, 4].
lower in HA-treated rats compared with rats treated with Dia- In extreme cases, ultrafiltration failure and reduced small-
neal alone (46% lower for albumin, P , 0.001; 33% lower for solute clearance may lead to inadequacy or even termina-
total protein, P , 0.001). The total drained volume after a
tion of peritoneal dialysis.four hour dwell was 29% higher in the HA group compared
In recent years, several modifications of the composi-with the control (P , 0.001), yielding a positive net ultrafiltra-
tion in the HA group versus a negative net ultrafiltration in tion of peritoneal dialysis solutions, such as neutral pH
controls. Peritoneal clearances of urea and creatinine tended and the elimination of glucose degradation products,
to be elevated in HA-treated rats, while clearances of total have been proposed to improve the biocompatibility ofprotein and albumin tended to be lower. Dialysate effluent
dialysis solutions. Results of in vitro experiments withfrom rats exposed to HA contained a lower percentage of
neutrophils (8.8 6 6.7 vs. 22.8 6 9.5%, P , 0.01) and lower such new solutions are promising [5, 6], and verification
levels of the cytokines, tumor necrosis factor-a (11.2 6 14.7 of the advantages of these solutions is eagerly awaited
in the clinic. Nevertheless, repeated intraperitoneal infu-
sions of PD solutions, even those that show high biocom-Key words: peritoneal dialysis, dialysate, membrane permeability,
mucopolysaccharide. patibility when tested in vitro, may produce nonspecific
irritation of the peritoneum and a subsequent inflamma-
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rats to a once-daily intraperitoneal infusion of dialysis 3.86% glucose supplemented with 10 mg/dL HA (Gen-
zyme Pharmaceuticals, Cambridge, MA, USA). The HAsolution supplemented with glycosaminoglycans im-
proved net ultrafiltration when compared with animals used in this study had an average molecular weight rang-
ing between 1.8 3 106 and 2.4 3 106 D. This moleculartreated with standard dialysis solutions [7, 8]. Glycos-
aminoglycans are macromolecules that regulate various weight was selected because high molecular weight HA,
in contrast to low molecular weight HA, is known toprocesses within connective tissues and interstitial spaces
[9]. Hyaluronan (HA) is a high molecular weight glycos- have anti-inflammatory properties [16]. High molecular
weight HA also appears to exert greater effects on ultra-aminoglycan produced in great amounts within the peri-
toneal cavity of continuous ambulatory peritoneal dial- filtration in acute rat studies [17]. The concentration
of HA (10 mg/dL) was chosen based on our previousysis patients [10]. Both peritoneal mesothelial cells and
fibroblasts produce HA, and HA synthesis is increased experiments [8]. Dialysis solutions in each group were
also supplemented with antibiotics (5 mg/L gentamicinduring episodes of peritonitis [11, 12]. HA is known to
play an important role during both acute and chronic and 50 mg/L cefuroksin). Infused solutions were allowed
to dwell and to be absorbed gradually from the perito-inflammation within connective tissue, modulating the
intensity of that process [13, 14]. In peritoneal dialysis neal cavity.
patients, Yamagata et al observed a positive correlation
Evaluation of peritoneal permeabilitybetween the duration of dialysis and the amount of HA in
the dialysate effluent, suggesting a relationship between Peritoneal permeability was evaluated using a four-
hour peritoneal equilibration test (PET). PETs were per-HA synthesis and chronic exposure to peritoneal dialysis
solutions [15]. formed in all rats four days after implantation of the
peritoneal catheter (PET 1) and again after four weeksTo investigate the effects of exogenous HA during
repeated exposure of the peritoneum to dialysis solu- of treatment with the control and test solutions (PET
2). On the day preceding the PET, animals were infusedtions, we infused rats twice daily for four weeks with a
with the dialysis fluid only once, in the morning, to ensurestandard hypertonic dialysis solution or with the same
its complete absorption from the peritoneal cavity priorsolution supplemented with 10 mg/dL HA. Our results
to the start of the PET. At each PET, animals weresuggest that exogenous HA, added to the dialysis solu-
infused with 30 mL of Dianeal solution containing 3.86%tion, may improve peritoneal ultrafiltration and reduce
glucose (without HA). Dialysate samples (1 mL) weremarkers of peritoneal inflammation or injury during
taken at time 0 (immediately after infusion), 30, 60, 120,chronic peritoneal dialysis.
and 240 minutes after infusion for measurement of urea,
creatinine, glucose, albumin, and total protein. Blood
METHODS samples were taken from the tail vein, under ether anes-
Experiments were performed on male Wistar rats (av- thesia, at the beginning and at the end of the PET. During
erage weight of 325 6 26 g). Initially, under ether anes- the PET, animals were awake and had free access to
thesia and sterile conditions, the abdominal cavity was water and food.
opened, and an omentectomy was performed. A perito- Concentrations of urea, creatinine, and glucose in se-
neal catheter with two dacron cuffs was inserted into the rum and dialysate were measured using enzymatic meth-
peritoneal cavity, and one dacron cuff was attached with ods (Analco, Warsaw, Poland). Albumin concentrations
sutures to the abdominal muscle. The distal part of the were measured using bromcocresol green (Sigma Chemi-
catheter was tunneled subcutaneously to the back side of cal Co., St. Louis, MO, USA), and total protein was
the rat’s neck and exteriorized at that site. The external measured by the method of Lowry et al [18]. Peritoneal
dacron cuff of the catheter was sutured to the skin of permeability of urea, creatinine, albumin, and total pro-
the neck. During the following three days, the animals tein was expressed as the dialysate to serum ratio (D/S).
were infused once daily with Dianeal peritoneal dialysis Glucose permeability was expressed as the ratio of glu-
solution containing 1.36% glucose (Baxter Healthcare cose concentration in the dialysate at a designated time
Corporation, Deerfield, IL, USA). Infused solution was to its concentration in the infused dialysis solution
left to be absorbed from the abdominal cavity. (D/D0). Peritoneal clearances for urea, creatinine, albu-
min, and total protein were calculated by multiplication
Experimental procedure of the total drained volume (including residual volume)
Four days after insertion of the peritoneal catheters, by the D/S ratio obtained at four hours during PET 2.
12 rats were randomly divided into two groups of six
Evaluation of peritoneal volumerats each. Control animals were infused twice a day with
20 mL of Dianeal containing 3.86% glucose (Baxter For PET 1, dialysate was drained at the end of the
Healthcare Corporation), and those in the treatment four-hour dwell by gravity, and its volume was measured
by weight. For PET 2, intraperitoneal dialysate volumegroup were infused with 20 mL of Dianeal containing
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was determined at designated time periods by calculation sate samples obtained during PET 1 and similar samples
obtained on the day preceding PET 2. Peritoneal cellof the dilution of a macromolecular marker, after correc-
counts were determined using a Neubauer chamber, andtion for absorption from the peritoneal cavity. The vol-
the cell differential was determined in cell smears follow-ume marker, blue dextran (Sigma Chemical Co.), was
ing Giemsa staining of the cytospinned cell pellets. Totaladded to the infused dialysis solution at a concentration
cell counts were approximated from cells per milliliterof 100 mg/dL, and the concentration of blue dextran in
and the total drained volume, which was not correctedthe collected dialysate samples was measured colorimet-
for residual volume. Peritoneal cell counts and differentialrically at 620 nm by comparison of data with a standard
were also determined in rats that were not exposed tocurve. Dialysate volume at each time period (n) was
dialysis solutions. In these animals, the peritoneal cavitycalculated according to the following formula:
was opened after sacrifice and filled with 20 mL of Hank’s
solution. After one to two minutes of mixing, a sample ofVn 5
C0 3 V0
Cn
2 Abs 3 tn
fluid was drawn for cell counts and differential. Cytokine
levels [tumor necrosis factor-a (TNF-a), monocyte chemo-
where Vn is the dialysate volume at time n; C0 is the attractant protein-1 (MCP-1), and interleukin-10 (IL-10)]
concentration of the macromolecular marker in the dial- were measured in dialysate samples (100 mL) using en-
ysate at time 0; V0 is the dialysate volume at time 0; Abs zyme-linked immunosorbent assay kits (ELISA) from
is the absorption rate of the macromolecular marker Biosource Europe S.A. (Fleurus, Belgium). Detection
from the peritoneal cavity; tn is time n; and Cn is the limits for the ELISA were 4, 8, and 5 pg/mL for TNF-a,
concentration of the macromolecular marker in the dial- MCP-1, and IL-10, respectively. The dialysate nitrite con-
ysate at time n. centration was measured colorimetrically with Griess
At the end of PET 2, after collecting the last dialysate reagent after reducing nitrates to nitrites with nitrate
sample, animals were sacrificed by an overdose of ether reductase (Boehringer Mannheim, Mannheim, Ger-
anesthesia, and the peritoneal cavity was opened. Resid- many) [19].
ual dialysate was collected from the peritoneal cavity
Morphometry of the peritoneal membranewith a Pasteur pipette, and its volume was measured by
weight. The peritoneal cavity was then infused with 20 After collection of residual dialysate at the end of PET
mL of Dianeal containing 3.86% glucose, and after mix- 2, biopsies of the liver were taken for light microscopy.
ing for one minute, a sample was drawn for measurement Similar biopsies were taken from rats never exposed to
of blue dextran concentration. The volume of residual dialysis solution (N 5 8 animals). All liver biopsies were
dialysate was calculated from the dilution of blue dextran taken from the edge of the right lobe of liver. Peritoneal
in the wash fluid according to the following formula: thickness was determined in hematoxylin and eosin-
stained tissue specimens by measurement of the com-
bined thickness of the mesothelium and submesothelialVresidual 5
Cwash 3 20
C240min 2 Cwash interstitium, lying between the mesothelium and liver
tissue. Twenty measurements were taken and averagedwhere Cwash is the concentration of blue dextran in the
for each specimen.dialysis fluid infused for washing the peritoneal cavity,
and C240min is the concentration of blue dextran in dialy- Measurement of hyaluronan content in
sate at 240 minutes of the dwell. peritoneal tissues
The total drained volume at the end of PET 2 was
Mesenteric biopsy specimens, each weighing approxi-calculated from the sum the volume obtained by weight
mately 100 mg, were incubated in digestion buffer con-and the residual volume.
taining 0.05 mol/L Tris-HCl, 0.01 mol/L CaCl2 (pH 7.2),The absorption rate of the macromolecular marker and 2.4 U/mL pronase (Sigma Chemical Co.) for 24 hours
from the peritoneal cavity was calculated for each animal at 558C. Tissue digestion was stopped by boiling at 1008C
from the difference between the absolute amount of for five minutes. Vials with digested tissue samples were
the marker in the collected dialysate after the four-hour centrifuged at 10,000 r.p.m. for one hour. After dis-
dwell and the initial amount infused into the peritoneal carding the lipid layer from the surface of fluid in each
cavity, divided by the time of the dwell (240 min). It was vial, the HA concentration in each sample was measured
assumed that absorption of the macromolecular marker by radioimmunoassay (Pharmacia AB, Uppsala, Swe-
from the peritoneal cavity was constant during the entire den). The concentration of HA in each sample was ex-
time of the dwell. pressed per mg of wet tissue.
Evaluation of markers of peritoneal inflammation Statistical analysis
Markers of peritoneal inflammation (cell counts, cell Results are presented as mean 6 SD. Statistical analy-
sis was performed using analysis of variance with postdifferential, and cytokine levels) were evaluated in dialy-
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Table 1. Transperitoneal permeability to small solutes and macromolecules at the peritoneal permeability test 1 (PET 1)
and after four weeks of exposure to the dialysis solution (PET 2)
PET 1 (D/S) PET 2 (D/S) D PET 2–PET 1
Control HA Control HA Control HA
Urea 0.98460.020 0.99260.020 0.93060.160 0.90560.160 20.05560.178 20.08760.157
Creatinine 0.79760.120 0.79060.141 0.85060.137 0.79660.065 0.05360.252 0.00560.122
Albumin 0.10360.023 0.09860.024 0.14360.043 0.06660.026a 0.04360.045 20.03260.022b
Total protein 0.06560.007 0.07560.013 0.07660.013a 0.05060.015a 0.01960.010 20.02560.020b
Values are expressed as dialysate/serum concentration (D/S) obtained at 4 hours during the PET. Negative numbers in the right hand columns indicate a decrease
in peritoneal permeability from PET 1 to PET 2.
Abbreviation HA is hyaluronan.
aP , 0.05 vs. PET 1
bP , 0.005 vs. the control group
hoc analysis using the Kruskal–Wallis test, multivariate
analysis of variance with post hoc analysis using the New-
man–Keuls test, Mann–Whitney, or Wilcoxon test, as




Transperitoneal permeabilities to urea, creatinine,
glucose, albumin, and total protein were similar in both
groups of rats at PET 1. After four weeks of exposure
to dialysis solution, permeability to albumin and total
protein increased slightly in the control group, whereas
both albumin and total protein permeability decreased
significantly in animals exposed to solution containing
HA (Table 1). Changes in protein permeability from
PET 1 to PET 2 were significantly different between
groups (P , 0.01 and P , 0.005 for albumin and total
protein, respectively). During PET 2, permeability to
albumin was significantly lower in the HA-treated group
at four hours (P , 0.001; Fig. 1B), and total protein
permeability was significantly lower at 0.5, 2, and 4 hours
(P , 0.05, P , 0.01, and P , 0.01, respectively; Fig. 2B).
There were no significant changes in the permeability to
urea or creatinine from PET 1 to PET 2 in either group,
and there were no differences between groups in small
solute permeability during PET 2 (Table 1). Absorption
of glucose from the dialysate was similar in both groups
Fig. 1. Transperitoneal equlibration (D/S) of albumin for rats im-during PET 1 and PET 2 (data not shown). planted with a peritoneal cathether and exposed briefly to peritoneal
dialysis solution (A, PET 1) and for rats exposed for four weeks (B,
Peritoneal volume, ultrafiltration, and clearances PET 2) to a hypertonic dialysis solution (control; h) or a solution
supplemented with 10 mg/dL hyaluronan (HA; j).Peritoneal volume, determined during PET 2 by dilu-
tion of blue dextran and at the end of PET 2 by gravimet-
ric methods, was significantly greater for rats treated with
HA compared with Dianeal solution alone. Peritoneal
at the end of PET 2 (determined gravimetrically with avolumes determined by macromolecular volume marker
correction for residual volume) was 34.2 6 3.8 mL forduring PET 2 were significantly greater for the HA-
the HA-treated group versus 26.6 6 5.2 mL for the con-treated group at 120 minutes (P , 0.005) and 240 minutes
(P , 0.001; Fig. 3). The mean volume of drained dialysate trol group (P , 0.001). Net ultrafiltration was therefore
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Table 2. Differential of peritoneal leukocytes at baseline (PET 1)
and after four weeks of infusion of dialysis solutions
( just prior to PET 2)
PET 1 PET 2
Control HA Control HA
Macrophages 38.764.0 40.065.7 36.063.7 49.262.9a
Neutrophils 18.363.1 15.261.9 22.869.5 8.866.7a
Eosinophils 18.863.7 16.762.3 18.869.9 15.565.3
Monocytes 8.861.3 10.062.3 6.362.0 10.362.7a
Lymphocytes 14.064.2 16.861.8 15.265.3 14.764.0
Basophils 0.860.8 0.860.4 0.560.5 0.360.5
Mast cells 0.560.5 0.560.5 0.360.5 1.261.0
Values are the percentage of total cells. Approximate total cell counts are
provided in the text.
aP , 0.05 vs. the control group
negative (23.4 mL) in the control group and positive
(4.2 mL) in animals treated with HA.
There was a trend toward higher peritoneal clearances
of urea (control 25.1 6 9.3 and HA 30.9 6 5.3 mL/4 h)
and creatinine (control 22.6 6 5.7 and HA 27.3 6 4.2
mL/4 h) and lower clearances of albumin (control 3.4 6
1.5 and HA 2.4 6 1.1 mL/4 h) and total protein (control
2.0 6 0.6 and HA 1.7 6 0.4 mL/4 h) in animals treated
with HA, but these differences were not significant.
Dialysate cell counts and cytokine levels
In untreated rats (N 5 6), the total number of perito-Fig. 2. Transperitoneal equlibration (D/S) of total protein for rats im-
neal cells (harvested by washing the peritoneal cavityplanted with a peritoneal cathether and exposed briefly to peritoneal
dialysis solution (A, PET 1) and for rats exposed for four weeks (B, with Hanks solution) was 24.1 3 106 6 5.7 3 106, of
PET 2) to a hypertonic dialysis solution (control; h) or a solution which macrophages accounted for 36.3 6 10.9%, neutro-supplemented with 10 mg/dL hyaluronan (HA; j).
phils 1.2 6 0.8%, eosinophils 28.3 6 6.0%, monocytes
14.7 6 5.9%, lymphocytes 16.5 6 5.9%, and mast cells
3.0 6 3.1% of the total cells. In rats implanted with a
peritoneal catheter and exposed to dialysis solution for
four days, total cell counts increased to approximately
71 3 106 6 40 3 106 cells in the control group and
approximately 70 3 106 6 48 3 106 cells in the group
randomized to receive HA, respectively. The percentage
of neutrophils in the dialysate also increased from 1.2 6
0.8% to 18.3 6 3.1% in the control group and 15.2 6
1.9% in the group to receive HA (P , 0.05 vs. untreated
rats; Table 2). There was no difference in cell counts or
differential between the two groups at PET 1.
After four weeks of exposure to dialysis solutions,
dialysate cell counts obtained from four-hour effluents
(obtained prior to PET 2) were lower in both groups
(approximately 47.3 3 106 6 21.7 3 106 cells in the
control group and approximately 59.4 3 106 6 24.0 3
106 cells in the HA group). In contrast to the control
group, in which the proportion of neutrophils increased,
Fig. 3. Dialysate volumes during PET 2 calculated from the dilution there was a marked reduction in the proportion of neu-
of a macromolecular volume marker (blue dextran; discussed in the trophils in dialysate samples obtained from rats exposedMethods section). Symbols are: (h) control; (j) hyaluronan.
to solution containing HA (8.8 6 6.7 vs. 22.8 6 9.5% in
control, P , 0.01; Table 2). The proportions of macro-
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Table 3. Dialysate concentration of cytokines and nitrites at baseline (PET 1) and after four weeks (PET 2) of intraperitoneal infusion of
Dianeal 3.86% (Control) or Dianeal 3.86% containing 10 mg/dL hyaluronan (HA)
PET 1 PET 2 D PET 22PET 1
Control HA Control HA Control HA
TNF-a pg/mL 4.461.4 3.861.6 42.3635.3 11.2614.7a 38.0634.9 7.4615.4a
MCP-1 pg/mL 14.162.8 14.164.3 4026258 72.0686.5a 3886260 57.9688.8a
II-10 pg/mL 15.768.0 18.269.1 87.0630.3 45.4649.7 71.4634.6 27.2653.8
Nitrites nmol/mL 4.560.8 3.661.1 12.5610.6 5.362.8 8.1610.6 1.663.1
Mean changes in dialysate cytokines (D PET 2-PET 1) are also presented.
aP , 0.05 vs. the control group
phages and monocytes were correspondingly higher in
the HA-treated group.
Concentrations of cytokines and nitrites in the four-
hour effluent dialysate were similar in both groups at
PET 1. Interestingly, after four weeks of exposure to
dialysis solutions, cytokine and nitrite levels increased
in effluents from rats exposed to hypertonic solution
without HA, whereas these increases were markedly at-
tenuated in animals exposed to solution containing HA
(Table 3). Concentrations of TNF-a and MCP-1 were
73% (P , 0.05) and 82% (P , 0.02) lower, respectively,
in dialysate samples obtained at week 4 from the HA-
treated rats compared with rats exposed to Dianeal
alone. There was also a trend toward lower IL-10 and
nitrite levels in dialysate from HA-treated rats as com-
Fig. 4. Hyaluronan content of peritoneal tissue (mesentery) in un-pared with the control group (Table 3).
treated rats and rats exposed to dialysis solution without (Dianeal
control) or with 10 mg/dL HA. *P , 0.05 vs. untreated rats; †P , 0.01
Peritoneal morphometry vs. control rats.
Peritoneal thickness (mesothelium plus interstitium)
from liver biopsies was significantly greater in animals
exposed for four weeks to dialysis solutions compared
repair [13, 16, 20]. Inflammatory reactions in connectivewith animals never exposed to dialysis solutions (12.0 6
tissue are followed by increased local production of HA,4.8 mm for the Dianeal control group; 11.2 6 7.7 mm for
and HA synthesis is up-regulated by proinflammatorythe HA group; vs. 3.01 6 0.73 mm for untreated rats, P ,
cytokines [11, 21, 22]. HA may protect against tissue0.05 for untreated vs. both treated groups). There was
damage during inflammation by scavenging free radicalsno difference in peritoneal thickness between the control
[23] or by inhibiting elastase release from activated leu-and HA-treated groups.
kocytes [24]. HA has also been shown to prevent the
excessive growth of connective tissue, and the presencePeritoneal hyaluronan content
of hyaluronic acid in wound fluid is associated with heal-In rats treated with Dianeal containing HA, the HA
ing of fetal wounds without scar formation [25]. Prelimi-content in mesenteric tissue samples was 48% higher
nary studies of the effect of HA on scar-free woundthan that from rats exposed to Dianeal alone (0.187 6
healing in adults have been promising [26, 27].0.026 mg/mg wet tissue compared with 0.126 6 0.028
In patients treated by peritoneal dialysis, intraperito-mg/mg for the control group, P , 0.01). Both groups of
neal production of HA increases dramatically duringrats exposed to dialysis solution had significantly greater
episodes of peritonitis [10, 11], consistent with a roleperitoneal HA content than untreated animals (0.105 6
for HA in modulating peritoneal inflammation and in0.009 mg/mg wet tissue, N 5 6, P , 0.05 vs. both treated
peritoneal wound healing following peritonitis. HA con-groups; Fig. 4).
centrations in the dialysis effluent also increase with the
duration of dialysis [15], possibly related to the chronic
DISCUSSION exposure of the peritoneal membrane to dialysis solu-
tions. During peritoneal dialysis, locally produced HAHyaluronan is known to modulate both acute and
chronic inflammatory reactions and to enhance tissue is removed from the peritoneal cavity at each fluid ex-
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change. As a result, HA may never achieve its optimal to be important in reducing transport of protein across
the glomerular basement membrane [31, 32]. We haveconcentration for prevention of tissue damage in the
peritoneal cavity. Thus, we hypothesized that exogenous also previously observed in rats that treatment with dial-
ysis fluid supplemented with glycosaminoglycans seemedHA, added to the dialysis solution, may protect the peri-
toneal membrane from inflammation and damage caused to reduce peritoneal protein loss [7, 8]. Importantly, Baz-
zato et al have demonstrated a decrease in peritonealby the chronic exposure to peritoneal dialysis solutions.
In our experiments, rats treated with dialysis solution protein loss following dialysis of continuous ambulatory
peritoneal dialysis patients for one month with a solutioncontaining HA had significantly fewer peritoneal neutro-
phils, despite similar numbers of total peritoneal cells, containing a mixture of heparan and dermatan sulfate
[33]. Although not significantly different between groups,when compared with rats exposed for four weeks to
hypertonic dialysis solution alone. In addition, dialysate clearance of small solutes (urea, creatinine) trended to
be higher for rats exposed to solution containing HA,levels of proinflammatory cytokines, TNF-a and MCP-1,
were significantly lower when HA was added to the dial- whereas clearance of macromolecules (that is, proteins)
tended to be lower. These opposite directions in theysis solution. These data suggest that exogenous HA may
reduce peritoneal inflammation or leukocyte activation peritoneal clearances of small and large molecules, both
of which are favorable for peritoneal dialysis therapy,that is associated with exposure to dialysis solutions in
this model. Our study did not demonstrate a significant imply that the lower concentrations of proteins in the
effluent dialysate from HA-treated rats are due not onlydifference in the thickness of the peritoneal interstitium
when control animals were compared with rats treated to their dilution with increased dialysate volumes, but
also reflect decreased permeability of the peritoneum towith HA. However, we examined only one peritoneal
biopsy from each animal, and the length of exposure to charged macromolecules.
Ultimately, long-term supplementation of the dialysisdialysis solution may have been too short to observe
significant differences between groups. Further studies fluid with HA may prevent peritoneal damage and im-
prove the efficiency of peritoneal dialysis by improvingare required to determine the effects of HA administra-
tion on peritoneal morphology in this model. ultrafiltration and decreasing peritoneal permeability to
protein. By replacing HA lost during repeated dialysisHyaluronan has been shown to increase net ultrafil-
tration when administered with the dialysis solution dur- exchanges, this approach may mimic natural homeostatic
mechanisms that operate within the peritoneal cavity, ining acute exchanges in rats [17, 28]. This increase in
ultrafiltration can be explained by a decrease in fluid which locally produced HA may modulate inflammation
reabsorption, which, in turn, has been explained by a and enhance the process of wound healing during perito-
decrease in the hydraulic conductivity of the connective neal dialysis. Supplementation of the dialysis solution
tissue in the peritoneal interstitium [17, 28–30]. Ac- with exogenous HA may help to maintain this homeosta-
cording to this hypothesis, the decrease in hydraulic con- sis and thereby decrease the intensity of intraperitoneal
ductivity of the peritoneal interstitium impedes fluid re- inflammation and reduce the damage induced by perito-
absorption, which depends on fluid reuptake into the nitis or chronic exposure to dialysis solutions.
venular end of the microvessels, but does not interfere
Reprint requests to Dr. Andrzej Bre¸borowicz, Department of Patho-with water flow into the peritoneal cavity induced by the physiology, Poznan Medical School, ul. Swiecickiego 6, 60-781 Poznan,
osmotic gradient created by glucose. Although HA was Poland.
E-mail: abreb@usoms.poznan.plnot included in the dialysis fluid during PET 2 in this
study, we observed an increase of ultrafiltration and peri-
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